DiaMedica Therapeutics Inc.
DMAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $167,535 | $162,379 | $232,505 |
| - Cash | $3,326 | $4,109 | $2,589 | $3,025 |
| + Debt | $157 | $292 | $316 | $340 |
| Enterprise Value | – | $163,718 | $160,106 | $229,820 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$18 | $0 | $0 | -$11 |
| % Margin | – | – | – | – |
| EBITDA | -$8,596 | -$8,004 | -$8,133 | -$7,880 |
| % Margin | – | – | – | – |
| Net Income | -$8,620 | -$7,699 | -$7,707 | -$7,900 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.17 | -0.18 | -0.18 | -0.18 |
| % Growth | 5.6% | 0% | 0% | – |
| Operating Cash Flow | -$6,605 | -$7,598 | -$7,149 | -$6,434 |
| Capital Expenditures | -$16 | -$6 | -$12 | -$7 |
| Free Cash Flow | -$6,621 | -$7,604 | -$7,161 | -$6,441 |